Acta Pharmaceutica Sinica B
|
2026, 16(6): 3680-3697
• Original articles •
Syringin disrupts the DLAT/MYC axis to dampen TAM polarization and suppress hepatocellular carcinoma progression
Full
Lingyun Xiao, Jiawei Lv, Yuan Lu, Zun Li, Liang-Mei Yang, Zheng Li, Shu Liang, Ke-Bin Huang, Xiongjun Wang
Affiliations
doi: 10.1016/j.apsb.2026.03.036
Outline
Tumor-associated macrophages (TAMs) are pivotal drivers of hepatocellular carcinoma (HCC) progression, and blocking TAM M2 polarization has the potential to dampen tumor microenvironment remodeling. In this study, we screened a series of phenylethanoid and phenylpropanoid glycosides and identified syringin as a natural compound capable of inhibiting M2 polarization while promoting M1 polarization in macrophages. Single-cell RNA sequencing confirmed that syringin reduced TAM M2 polarization and significantly impaired tumor microenvironment remodeling. In detail, syringin indirectly reduced the stability of MYC proto-oncogene protein (MYC), which is required for driving a broad set of targets, including Arg1, Il10, Ym1, Mrc1, and Cd274. Using affinity-based protein profiling (ABPP), we revealed dihydrolipoamide S-acetyltransferase (DLAT) as a direct target of syringin. DLAT possesses protein acetyltransferase activity that acetylates MYC at K148. Syringin bound DLAT at residues R430 and N576 and disrupted the DLAT/MYC axis, thereby blocking MYC acetylation and promoting the ubiquitination and degradation of MYC protein. Additionally, syringin enhanced the efficacy of programmed cell death protein 1 blockade in mouse and patient-derived xenograft models, offering a potential adjunctive agent for HCC.
Hepatocellular carcinoma (HCC)
/
Tumor-associated macrophages (TAMs)
/
Macrophage polarization
/
Dihydrolipoamide S-acetyltransferase (DLAT)
/
MYC degradation
/
Syringin
/
Single-cell RNA sequencing (scRNA-seq)
/
Tumor microenvironment (TME)
Lingyun Xiao, Jiawei Lv, Yuan Lu, Zun Li, Liang-Mei Yang, Zheng Li, Shu Liang, Ke-Bin Huang, Xiongjun Wang.
Syringin disrupts the DLAT/MYC axis to dampen TAM polarization and suppress hepatocellular carcinoma progression[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(6)
: 3680
-3697
.
DOI: 10.1016/j.apsb.2026.03.036
Year 2026 volume 16 Issue 6
PDF
6
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.03.036
- Receive Date:2025-06-30
- Online Date:2026-09-17